Who Paid My Doc
Pneumovax 23
Biological Vaccine
NDC 0006-4943-00
General payments
$1,223,037
Research payments
$21,741,509
Through program year 2025, $1,223,037 in general payments and $21,741,509 in research payments were reported against Pneumovax 23 (Vaccine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $34,050 | 20 |
| 2025 | Research | $1,214,990 | 29 |
| 2024 | General | $10,024 | 20 |
| 2024 | Research | $1,163,681 | 93 |
| 2023 | General | $116,344 | 5,357 |
| 2023 | Research | $2,394,091 | 99 |
| 2022 | General | $253,665 | 14,197 |
| 2022 | Research | $14,741,165 | 192 |
| 2021 | General | $245,733 | 15,278 |
| 2021 | Research | $874,484 | 30 |
| 2020 | General | $180,981 | 6,591 |
| 2020 | Research | $1,000,359 | 27 |
| 2019 | General | $382,239 | 17,868 |
| 2019 | Research | $352,739 | 34 |
Breakdown
The top 5 of 19 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
59,331 general · 504 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.